BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23878324)

  • 1. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis.
    Castellanos-Gonzalez A; White AC; Ojo KK; Vidadala RS; Zhang Z; Reid MC; Fox AM; Keyloun KR; Rivas K; Irani A; Dann SM; Fan E; Maly DJ; Van Voorhis WC
    J Infect Dis; 2013 Oct; 208(8):1342-8. PubMed ID: 23878324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.
    Huang W; Choi R; Hulverson MA; Zhang Z; McCloskey MC; Schaefer DA; Whitman GR; Barrett LK; Vidadala RSR; Riggs MW; Maly DJ; Van Voorhis WC; Ojo KK; Fan E
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533246
    [No Abstract]   [Full Text] [Related]  

  • 3. A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice.
    Castellanos-Gonzalez A; Sparks H; Nava S; Huang W; Zhang Z; Rivas K; Hulverson MA; Barrett LK; Ojo KK; Fan E; Van Voorhis WC; White AC
    J Infect Dis; 2016 Dec; 214(12):1850-1855. PubMed ID: 27738055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection.
    Ndao M; Nath-Chowdhury M; Sajid M; Marcus V; Mashiyama ST; Sakanari J; Chow E; Mackey Z; Land KM; Jacobson MP; Kalyanaraman C; McKerrow JH; Arrowood MJ; Caffrey CR
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6063-73. PubMed ID: 24060869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.
    Kuhlenschmidt TB; Rutaganira FU; Long S; Tang K; Shokat KM; Kuhlenschmidt MS; Sibley LD
    Antimicrob Agents Chemother; 2016 Jan; 60(1):570-9. PubMed ID: 26552986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Conditional Protein Degradation System To Study Essential Gene Function in Cryptosporidium parvum.
    Choudhary HH; Nava MG; Gartlan BE; Rose S; Vinayak S
    mBio; 2020 Aug; 11(4):. PubMed ID: 32843543
    [No Abstract]   [Full Text] [Related]  

  • 7. Prodrug activation by Cryptosporidium thymidine kinase.
    Sun XE; Sharling L; Muthalagi M; Mudeppa DG; Pankiewicz KW; Felczak K; Rathod PK; Mead J; Striepen B; Hedstrom L
    J Biol Chem; 2010 May; 285(21):15916-22. PubMed ID: 20231284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum.
    Li K; Nader SM; Zhang X; Ray BC; Kim CY; Das A; Witola WH
    PLoS Pathog; 2019 Jul; 15(7):e1007953. PubMed ID: 31356619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel CDPK1 inhibitor--a potential treatment for cryptosporidiosis in calves?
    Lendner M; Böttcher D; Delling C; Ojo KK; Van Voorhis WC; Daugschies A
    Parasitol Res; 2015 Jan; 114(1):335-6. PubMed ID: 25398685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.
    Schaefer DA; Betzer DP; Smith KD; Millman ZG; Michalski HC; Menchaca SE; Zambriski JA; Ojo KK; Hulverson MA; Arnold SL; Rivas KL; Vidadala RS; Huang W; Barrett LK; Maly DJ; Fan E; Van Voorhis WC; Riggs MW
    J Infect Dis; 2016 Dec; 214(12):1856-1864. PubMed ID: 27923949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.
    Hulverson MA; Vinayak S; Choi R; Schaefer DA; Castellanos-Gonzalez A; Vidadala RSR; Brooks CF; Herbert GT; Betzer DP; Whitman GR; Sparks HN; Arnold SLM; Rivas KL; Barrett LK; White AC; Maly DJ; Riggs MW; Striepen B; Van Voorhis WC; Ojo KK
    J Infect Dis; 2017 Apr; 215(8):1275-1284. PubMed ID: 28329187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptic parasite revealed improved prospects for treatment and control of human cryptosporidiosis through advanced technologies.
    Jex AR; Smith HV; Nolan MJ; Campbell BE; Young ND; Cantacessi C; Gasser RB
    Adv Parasitol; 2011; 77():141-73. PubMed ID: 22137584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
    Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
    Rueda C; Fenoy S; Simón F; Del Aguila C
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1150-2. PubMed ID: 18160525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel treatment strategies and drugs in development for cryptosporidiosis.
    Chavez MA; White AC
    Expert Rev Anti Infect Ther; 2018 Aug; 16(8):655-661. PubMed ID: 30003818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
    Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
    Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
    Larson ET; Ojo KK; Murphy RC; Johnson SM; Zhang Z; Kim JE; Leibly DJ; Fox AM; Reid MC; Dale EJ; Perera BG; Kim J; Hewitt SN; Hol WG; Verlinde CL; Fan E; Van Voorhis WC; Maly DJ; Merritt EA
    J Med Chem; 2012 Mar; 55(6):2803-10. PubMed ID: 22369268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
    Morales Gomez MA
    Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Cryptosporidium parvum infection in immunocompetent and immunocompromised mice and its role in triggering intestinal dysplasia.
    Abdou AG; Harba NM; Afifi AF; Elnaidany NF
    Int J Infect Dis; 2013 Aug; 17(8):e593-600. PubMed ID: 23291034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against
    Khan SM; Bajwa MR; Lahar RY; Witola WH
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0056923. PubMed ID: 37655889
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.